<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944708</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-HNCNS-2015-04</org_study_id>
    <nct_id>NCT02944708</nct_id>
  </id_info>
  <brief_title>Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Randomized Phase III Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Guangxi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy of maintenance chemotherapy for the
      treatment of metastatic nasopharyngeal carcinoma. Participants will be randomized to 3 arms.
      Arm 1, control group, participants will receive only 4-8 cycles of conventional chemotherapy;
      arm 2, participants will receive 6 cycles of maintenance chemotherapy after conventional
      chemotherapy; arm 3, experiment arm, after conventional chemotherapy, participants will
      receive maintenance chemotherapy until disease progression or intolerable toxicities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3 randomized clinical trial to determine the efficacy of maintenance
      chemotherapy for the treatment of metastatic chemotherapy and how it should be delivered.
      Participants will be randomized to 3 arms. Arm 1 (control group), participants will receive
      only conventional chemotherapy; arm 2 (experimental group), participants will receive up to 6
      cycles of maintenance chemotherapy after conventional chemotherapy; arm 3 (experimental
      group), after conventional chemotherapy, participants will receive maintenance chemotherapy
      until disease progression or intolerable toxicities. Participants in all 3 arms will receive
      similar conventional chemotherapy. Four to eight cycles of conventional chemotherapy with
      platinum-based regimen is preferred. Maintenance chemotherapy should use one of the regimens:
      S1 (40mg, twice a day for 14 days, every 3 weeks), capecitabine (1000mg/m^2, twice a day for
      14 days, every 3 weeks) or Tegafur-uracil (100mg/m^2, q8h, for 14 days, every 3 weeks). The
      response of treatment will be evaluated according to RECIST criteria. Adverse events will be
      documented according to CTCAE v4.03.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From the time point the patients are included in the study, median of 3 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the time point the patients are included in the study, median of 3 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>From the time point the patients are included in the study, median of 3 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Conventional chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will only receive 4-8 cycles of cisplatin-based regimen. TPF ( docetaxel, cisplatin and 5-fluorouracil ), TP (docetaxel and cisplatin), GP (gemcitabine and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens are preferred.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance chemotherapy 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive 6 cycles of oral fluoropyrimidine monotherapy as maintenance therapy, in addition to 4-8 cycles of cisplatin-based standard chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance chemotherapy 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive oral fluoropyrimidine maintenance therapy until disease progression or intolerable toxicities, after 4-8 cycles of cisplatin-based standard chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional chemotherapy</intervention_name>
    <arm_group_label>Conventional chemotherapy</arm_group_label>
    <arm_group_label>Maintenance chemotherapy 1</arm_group_label>
    <arm_group_label>Maintenance chemotherapy 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance chemotherapy 1</intervention_name>
    <arm_group_label>Maintenance chemotherapy 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance chemotherapy 2</intervention_name>
    <arm_group_label>Maintenance chemotherapy 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 and ≤ 70 years

          -  Histologically confirmed nasopharyngeal carcinoma, WHO (World Health Organization)
             classification II/III

          -  With distant metastasis

          -  With measurable lesions that can be detected by imaging studies

          -  Achieving PR (partial response) after 4 cycles of conventional chemotherapy

          -  Life expectancy ≥ 6 months

          -  ECOG (Eastern Cooperative Oncology Group): 0-1, no significant active concurrent
             medical illnesses

          -  Adequate laboratory values within 30 dyas of enrollment to study defined as follows: N
             &gt; 2000/mm^3; PLT (platelet count) &gt; 100,000/mm^3; total bilirubin &lt; 1.5mg/dl; AST
             (aspartate aminotransferase)/ALT (alanine aminotransferase) &lt; 1.5 ULN (upper limit of
             normal); SCr (serum creatinine) &lt; 1.5mg/dl; CCR (creatinine clearance rate) &gt; 60ml/min

          -  Willing to accept adequate contraception for women with childbearing potential

          -  Ability to understand character and individual consequences of the clinical trial

          -  Willing to sign the written informed consent; Informed consent must be signed before
             the enrollment in the trial

        Exclusion Criteria:

          -  Received previous treatment for metastatic disease

          -  Pregnant or lactating women

          -  A diagnosis of malignancy other than CIS (carcinoma in situ) of the cervix, BCC (basal
             cell carcinoma) and SCC (squamous cell carcinoma) of the skin within the past 5 years

          -  Refusal of the patient to participate into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiade J Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Proton and Heavy Ion Center,Shanghai, SPHIC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Kong, MD</last_name>
    <email>lin.kong@sphic.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiyi Hu, MD</last_name>
    <email>jiyi.hu@sphic.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Sun, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinshen Hong, MD</last_name>
      <email>hjs703@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Lin, MD</last_name>
      <email>linqin05@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Zhu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heming Lu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoqing Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Province Tumor Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaochang Gong, MD</last_name>
      <email>gxcanddw@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaochang Gong, MD</last_name>
      <email>gxcanddw@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201315</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaosu Hu, MD</last_name>
      <email>hucsu62@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201315</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Kong, MD</last_name>
      <email>lin.kong@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jiyi Hu, MD</last_name>
      <email>jiyi.hu@sphic.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jiade J Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye &amp; ENT Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengzi Wang, MD</last_name>
      <email>shengziwang@fudan.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre, Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>119082</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boon Cher Goh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Ching Lin, MD</last_name>
      <email>jclin@vghtc.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Lin Kong</investigator_full_name>
    <investigator_title>Consultant doctor, chair of head and neck cancer</investigator_title>
  </responsible_party>
  <keyword>maintenance chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

